Virtual Biopsy

A virtual biopsy captures the entire three-dimensional tumor landscape, not just a single core sample. By extracting thousands of features—including shape, first-order statistics, and texture matrices like GLCM and GLRLM—it quantifies the full spatial heterogeneity that a physical needle biopsy might miss due to sampling error.

Unlike surgical excision, a virtual biopsy can be repeated at every follow-up scan without patient risk. This enables delta-radiomics—the analysis of feature changes over time—to monitor treatment response, detect early resistance, and adapt therapeutic strategy dynamically.

Advanced virtual biopsies employ habitat imaging to partition a tumor into distinct sub-regions based on voxel-wise clustering of functional parameters. This reveals necrosis, proliferation, and hypoxia zones, mapping the evolutionary pressure landscape that drives metastasis.

To ensure clinical translatability, virtual biopsy workflows adhere to the Image Biomarker Standardisation Initiative (IBSI). This provides consensus-based reference values for feature computation, ensuring that a radiomic signature derived at one institution is reproducible across different scanners and sites.

The quantitative imaging phenotype is fused with genomic sequencing, pathology reports, and clinical data to create a holistic diagnostic model. This multi-modal fusion allows the virtual biopsy to correlate macroscopic image patterns with microscopic molecular drivers like gene expression profiles.

Using feature selection algorithms like LASSO and mRMR, a virtual biopsy distills thousands of features into a compact radiomic signature. This mathematical composite biomarker is validated against hard clinical endpoints such as overall survival, progression-free survival, and recurrence risk.

The high-throughput extraction of quantitative, mineable features from medical images to characterize tumor phenotype. This process converts standard-of-care CT, MRI, and PET scans into a high-dimensional data space, enabling the discovery of imaging biomarkers that correlate with underlying gene expression patterns and clinical outcomes.

An independent international collaboration providing consensus-based reference values and standardized nomenclature for radiomic feature computation. IBSI guidelines ensure that a virtual biopsy phenotype extracted at one institution is reproducible and directly comparable to one extracted at another, eliminating algorithmic variance.

A composite biomarker consisting of a selected panel of multiple quantitative imaging features combined via a mathematical model to predict a specific clinical endpoint. Unlike a single feature, a signature captures the complex, multi-parametric nature of tumor heterogeneity, serving as the direct non-invasive surrogate for molecular profiling.

A technique that partitions a tumor into distinct sub-regions based on voxel-wise clustering of functional or structural imaging parameters. By identifying spatially distinct physiological niches within a single lesion, habitat imaging quantifies intratumoral heterogeneity, revealing aggressive sub-clones that a global virtual biopsy might miss.

A statistical batch-effect correction method adapted from genomics to remove non-biological technical variance in radiomic features across different imaging scanners. This technique is critical for virtual biopsy, as it mitigates the center effect, allowing models trained on data from one hospital to generalize reliably to scans acquired at another.

The extraction and analysis of changes in quantitative imaging features over time or across multiple treatment cycles. While a single virtual biopsy provides a static phenotype, delta-radiomics captures the dynamic biological response to therapy, enabling early prediction of treatment efficacy or resistance.